Overview
Spastic paraplegia-neuropathy-poikiloderma syndrome is an extremely rare inherited condition that affects the nervous system and the skin. It is sometimes referred to by its Orphanet designation (ORPHA:2821). The hallmark features of this syndrome include spastic paraplegia (progressive stiffness and weakness of the legs due to damage in the nerve pathways of the spinal cord), peripheral neuropathy (damage to the nerves outside the brain and spinal cord causing numbness, tingling, or weakness in the hands and feet), and poikiloderma (a distinctive skin change that includes patches of thinning skin, changes in skin color, and visible small blood vessels). Together, these features create a multi-system condition that can significantly affect mobility and quality of life. Because this syndrome is so rare, only a handful of cases have been described in the medical literature. Symptoms typically begin in childhood or adolescence and tend to worsen slowly over time. Walking becomes increasingly difficult as leg stiffness and weakness progress, and the peripheral neuropathy can add further challenges with balance and sensation. The skin changes may appear early and can be cosmetically distressing. There is currently no cure for this condition. Treatment focuses on managing symptoms, including physical therapy to maintain mobility, medications to reduce muscle stiffness (spasticity), and dermatological care for the skin findings. A team of specialists is usually needed to provide comprehensive care.
Also known as:
Key symptoms:
Progressive leg stiffness and weakness (spastic paraplegia)Numbness or tingling in hands and feetDifficulty walking or unsteady gaitSkin color changes (lighter and darker patches)Thinning of the skinVisible small blood vessels on the skin (telangiectasia)Muscle wasting in the legs or feetReduced sensation in the limbsIncreased muscle tone and stiffness in the legsFoot deformities such as high arches or curled toesFatigue with physical activityDifficulty with fine motor tasks in the hands
Clinical phenotype terms (8)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Spastic paraplegia-neuropathy-poikiloderma syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Spastic paraplegia-neuropathy-poikiloderma syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Spastic paraplegia-neuropathy-poikiloderma syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Spastic paraplegia-neuropathy-poikiloderma syndrome.
Community
No community posts yet. Be the first to share your experience with Spastic paraplegia-neuropathy-poikiloderma syndrome.
Start the conversation →Latest news about Spastic paraplegia-neuropathy-poikiloderma syndrome
No recent news articles for Spastic paraplegia-neuropathy-poikiloderma syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What genetic testing should be done to confirm the diagnosis?,How quickly is this condition likely to progress in my case?,What medications can help with the leg stiffness and nerve pain?,How often should I have physical therapy, and what exercises can I do at home?,Are there any clinical trials or research studies I could participate in?,What specialists should be part of my care team?,What can be done to manage the skin changes?
Common questions about Spastic paraplegia-neuropathy-poikiloderma syndrome
What is Spastic paraplegia-neuropathy-poikiloderma syndrome?
Spastic paraplegia-neuropathy-poikiloderma syndrome is an extremely rare inherited condition that affects the nervous system and the skin. It is sometimes referred to by its Orphanet designation (ORPHA:2821). The hallmark features of this syndrome include spastic paraplegia (progressive stiffness and weakness of the legs due to damage in the nerve pathways of the spinal cord), peripheral neuropathy (damage to the nerves outside the brain and spinal cord causing numbness, tingling, or weakness in the hands and feet), and poikiloderma (a distinctive skin change that includes patches of thinning
How is Spastic paraplegia-neuropathy-poikiloderma syndrome inherited?
Spastic paraplegia-neuropathy-poikiloderma syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Spastic paraplegia-neuropathy-poikiloderma syndrome typically begin?
Typical onset of Spastic paraplegia-neuropathy-poikiloderma syndrome is childhood. Age of onset can vary across affected individuals.